Navigation Links
Adoption of Minimally Invasive Prostate Cancer Treatment Options Slow
Date:6/25/2008

Chemotherapy and Cryosurgery are underused prostate cancer treatments in

the US, according to Millennium Research Group

WALTHAM, Mass., June 25 /PRNewswire/ -- Millennium Research Group (MRG) conducted a detailed survey of over 140 US and European based urologists during the recent 2008 American Urological Association (AUA) Annual Meeting. Results of this study are analyzed in the US and European Urologist Survey: Prostate Cancer Treatment Trends 2008 report. Data from the study suggests that several minimally invasive prostate cancer treatment options are underused in both the US and Europe.

US urologists indicated that cryosurgery was underused, while European urologists felt that both cryosurgery and high-intensity focused ultrasound (HIFU) were underused. In both regions, insufficient data supporting the treatments and the need to refer patients to another specialist were considered the leading barriers to adoption.

"These barriers will need to be addressed before utilization rates can increase notably," says Barbara Prud'homme, Senior Analyst at Millennium Research Group. "Expensive equipment, poor results with early cryosurgery equipment, and physician familiarity with traditional treatments such as radical prostatectomy, have deterred many from performing these minimally invasive procedures. Moreover, many urologists see cryosurgery as a salvage operation after other treatments haven't worked. One positive sign for the adoption of these treatments is that US and European urologists indicated that their use of these treatments had increased over the past year."

Although urologists were underusing new minimally invasive treatments, they were aware of emerging treatment options, including gene therapy and autoimmune therapy. Urologists believed emerging treatments would eventually improve patient outcomes.

MRG's US and European Urologist Survey: Prostate Cancer Treatment Trends 2008 report examines urologi
'/>"/>

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cincinnati Adoption Agency Invited to Participate in Values Voter Presidential Debate
2. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
3. Award recognizes 2 decades of research that led to the adoption of risk adjustment tools
4. MedeFile Applauds U.S. Presidential Hopefuls for Advocating Widespread Adoption of Electronic Medical Records
5. The University of California at San Francisco Medical Center Pioneers System-wide Adoption of Masimo Rainbow SET Technology
6. New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies
7. Gladney Center for Adoption Receives Whole Health Grant from Aetna Foundation
8. The Gladney Center for Adoption Names Mark L. Melson as Executive Vice President/Chief Development Officer
9. Minimally Invasive Heart Surgery Research Wins N.I.H. Award
10. Novadaq launches PINPOINT: Companys first minimally invasive imaging system
11. Published Results Using AtriCure Minimally Invasive Products
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference 2Health News:Help Young Cancer Patients Enjoy Christmas This Season 2
Breaking Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 1Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non Clinical Data at 51st American Society of Hematology Annual Mee 6511 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 1CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 6509 3Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 1Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference 6507 2